What InxMed does

InxMed is a clinical-stage biotechnology company founded in late 2018 and headquartered in Nanjing, China, that develops oncology therapies targeting tumor defense mechanisms. The company's lead asset, Ifebemtinib (IN10018), is a highly selective, orally administered small-molecule focal adhesion kinase (FAK) inhibitor that has been administered to over 600 patients and is being evaluated in registrational trials for platinum-resistant ovarian cancer and in combination with KRAS G12C inhibitors for first-line non-small cell lung cancer and second-line plus colorectal cancer. The pipeline additionally includes first-in-class antibody-drug conjugates IN30758 and IN30718 plus OMTX705 co-developed with Oncomatryx, with linker-payload capabilities augmented through a license to Escugen's EZWi-Fit® platform.

The company's underlying technology thesis is that tumor stroma, cancer-associated fibroblasts, and integrin-mediated adhesion create physical and signaling barriers that blunt the efficacy of chemotherapy, targeted agents, immunotherapies, and ADCs. By combining a FAK inhibitor with these modalities, InxMed is positioning itself as a combination-therapy backbone rather than a standalone product, with development activities spanning the United States, China, Australia, and Canada and research footprints in Nanjing, Shanghai, Beijing, and (as of April 2025) Shenzhen.

InxMed is pre-revenue and has funded operations through venture capital, raising more than USD 130 million across Series A+ (2020), Series B (2022), Series B+ (2022), and Series C (2025) rounds, and has submitted an IPO application to the Hong Kong Stock Exchange. The planned commercial model relies on out-licensing global rights, co-development partnerships, and milestone or royalty income, supported by three China NMPA Breakthrough Therapy Designations and one US FDA Fast Track Designation that should accelerate paths to approval.

Name

InxMed

Legal name

InxMed (Nanjing) Co., Ltd.

Website

https://en.inxmed.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

InxMed is a clinical-stage Chinese biotech developing Ifebemtinib, a FAK inhibitor, and multiple first-in-class ADCs to overcome tumor treatment resistance and metastasis, targeting patients with KRAS-mutant and stroma-rich solid tumors.

Ownership category

akta.pro rank

Product category

Oncology Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)

akta.pro secondary industry

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• Focal adhesion kinase inhibitors
• Antibody-drug conjugates
• Oncology drug development
• Combination cancer therapy
• Tumor microenvironment targeting

Headquarters

HQ city

Shanghai

HQ country

China

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Drug Development and Commercialization: As a clinical-stage biotech company, InxMed is pre-revenue. They develop proprietary drug candidates through clinical trials and plan to commercialize through partnerships or direct sales upon regulatory approval. Revenue will come from product sales, royalties, and milestone payments from partnerships.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

InxMed is a clinical-stage biotechnology company developing a differentiated pipeline of novel cancer therapies that target tumor defense mechanisms, led by Ifebemtinib (IN10018), a highly selective oral focal adhesion kinase (FAK) inhibitor in registrational trials for KRAS G12C-mutant NSCLC, platinum-resistant ovarian cancer, and KRAS G12C-mutant colorectal cancer. The company also develops multiple first-in-class antibody-drug conjugates (ADCs) including IN30758, IN30718, and OMTX705, and pursues combination regimens with RAS pathway inhibitors and ADCs to overcome treatment resistance.

Product overview

InxMed is a clinical-stage biotechnology company developing a differentiated portfolio of novel cancer therapies targeting tumor defense mechanisms. The company's core product is Ifebemtinib (IN10018), a highly selective FAK inhibitor in registrational trials. The pipeline includes multiple ADCs (IN30758, IN30718, OMTX705) targeting tumor stroma and cancer-associated fibroblasts. The company focuses on combination therapies using FAK inhibitors with RAS pathway inhibitors and ADCs to overcome treatment resistance and metastasis. The technology platforms include translational medicine, antibody discovery, linker-payload conjugation, developability optimization, and pharmacodynamic evaluation.

Differentiator

Problem solved

Functional benefit

Products and services

• Ifebemtinib (IN10018) Highly selective, orally administered small-molecule inhibitor of focal adhesion kinase (FAK) for treating cancer treatment resistance and metastasis. Demonstrates therapeutic synergies with chemotherapy, targeted therapies, and immunotherapies. Lead candidate in registrational trials for platinum-resistant ovarian cancer and KRAS G12C-mutant NSCLC.
• IN30758 First-in-class antibody-drug conjugate (ADC) targeting a member of the integrin family overexpressed in the vast majority of solid tumors, including DXD-resistant cancers. Exhibits robust in vivo efficacy in CDX and PDX models and is well tolerated in cynomolgus monkeys.
• OMTX705 First-in-class FAP (fibroblast activation protein)-targeting ADC developed in collaboration with Oncomatryx. Targets FAPα expressed on cancer-associated fibroblasts surrounding tumor cells. InxMed owns commercialization rights in Asia.

Quantifiable outcome

• ORR of 90.3% and mPFS of 22.3 months in first-line KRAS G12C-mutant NSCLC with ifebemtinib + garsorasib combination
• +2 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered core and minor.

• ADC CompaniescoreStrategic or Co-development Partner · 8 November 2024InxMed is establishing collaborations with multiple ADC companies to advance ifebemtinib as an ideal combo partner for ADCs, potentially leading to revolutionary advancements in cancer therapy.
• EscugencoreOEM/ Whitelabel/ Licensing Partner · 20 December 2023License agreement for EZWi-Fit® linker-payload platform for development of next-generation tumor-associated antigens targeting ADCs. InxMed has rights for development, manufacturing, and commercialization.
• OncomatryxminorStrategic or Co-development Partner · 30 August 2023Collaboration to co-research and develop OMTX705 (FAP-targeting ADC) preclinically and clinically. InxMed owns commercialization rights in Asia.
• MSD (Merck & Co.)coreStrategic or Co-development Partner · 7 January 2020Clinical collaboration to evaluate IN10018 in combination with MSD's anti-PD-1 therapy pembrolizumab in pancreatic cancer patients. First global clinical collaboration between the two companies.
• RochecoreStrategic or Co-development Partner · 12 October 2019Clinical collaboration to evaluate IN10018 in combination with Roche's Cobimetinib (MEK inhibitor) in melanoma patients. Roche provides Cobimetinib for the clinical study.

Scale indicators6 records

Recent moves7 records

Expansion highlights7 records

Direct peers

• Verastem Oncology: Verastem Oncology is a US oncology company whose lead asset defactinib is also a FAK inhibitor, making it the most direct comparator to InxMed's Ifebemtinib. Both companies are pursuing FAK inhibition as a strategy to overcome tumor stroma and treatment resistance in oncology combinations.
• ArriVent Biopharma: ArriVent is a clinical-stage oncology company developing targeted therapies for solid tumors with a focus on biomarker-driven patient selection. Comparable as a similarly-sized, clinical-stage oncology company pursuing combination and biomarker-driven development strategies.
• Mersana Therapeutics: Mersana Therapeutics is a clinical-stage biotech developing a pipeline of ADCs with proprietary linker-payload platforms. Comparable as an ADC-focused developer leveraging platform technology and partnership-driven development, similar in pipeline-stage positioning to InxMed's ADC programs.

Regional players

• Innovent Biologics: Innovent is a leading Chinese biopharmaceutical company developing innovative oncology biologics including ADCs and immuno-oncology therapies. Comparable as a similarly-positioned Chinese biotech with a multi-modality oncology pipeline and global partnering ambitions.
• BeiGene: BeiGene is a Chinese-founded global oncology company with a portfolio of targeted therapies and immuno-oncology agents, including ADC and combination programs. Comparable in scale and Chinese-origin oncology focus with established global commercialization capability.
• Hansoh Pharmaceutical: Hansoh is one of China's largest innovative pharmaceutical companies with a broad oncology pipeline including targeted therapies. Comparable as an established Chinese oncology developer with commercialization infrastructure and global out-licensing activity.
• Junshi Biosciences: Junshi Biosciences is a Chinese biotech that developed the first China-approved PD-1 antibody (toripalimab) and is expanding into ADC and combination oncology. Comparable as a clinical-stage-to-commercial Chinese biotech focused on oncology innovation and global partnerships.
• Hutchmed: Hutchmed is a Hong Kong-listed Chinese-founded oncology and immunology company with multiple approved targeted therapies and global development partnerships. Comparable as a Hong Kong-listed Chinese oncology biotech that has achieved commercial-stage status through similar development pathways.
• GenFleet Therapeutics: GenFleet is a Chinese clinical-stage oncology company developing small molecule targeted therapies and biologics. Comparable as a Chinese oncology biotech with a similar development-stage profile and focus on novel mechanism oncology combinations.

Broad incumbents

• AstraZeneca: AstraZeneca is a global pharmaceutical company with established FAK inhibitor programs, a major ADC franchise (Datroway, Enhertu collaborations), and leadership in KRAS combination development. Comparable as a broad incumbent in the same oncology mechanism and combination spaces that InxMed targets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles21 records

Funding overview

Funding rounds5 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about InxMed